Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Neoplasms, Glandular and Epithelial 2Carcinoma 2Uterine Cervical Dysplasia 1Urogenital Neoplasms 1Ovarian Neoplasms 1Ovarian Diseases 1Neoplasms 1Neoplasm Metastasis 1Gonadal Disorders 1Genital Neoplasms, Female 1Genital Diseases, Female 1Female Urogenital Diseases and Pregnancy Complications 1Female Urogenital Diseases 1Endocrine System Diseases 1Endocrine Gland Neoplasms 1Adnexal Diseases 1

Interventions

Paclitaxel 7Cisplatin 6pembrolizumab 5Carboplatin 5Bevacizumab 5liposomal doxorubicin 3Gemcitabine 3trebananib 2niraparib 2interferon gamma-1b 2dostarlimab 2catumaxomab 2atezolizumab 2anlotinib 2Topotecan 2Radiotherapy, Intensity-Modulated 2Ocoxin 2Itraconazole 2Injections 2Hyperthermic Intraperitoneal Chemotherapy 2Drug Therapy 2Docetaxel 2vosaroxin 1vistusertib 1pertuzumab 1peginterferon alfa-2b 1olaparib 1nintedanib 1lanreotide 1epothilone B 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma × Ocoxin × Gynecologic × Clear all
NCT03549273 2024-02-07

Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions

Catalysis SL

Phase 2 Unknown
62 enrolled
Gynecologic

Carcinoma, Uterine Cervical Dysplasia, Neoplasms, Neoplasms, Glandular and Epithelial

NCT03562897 2022-07-06

Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer

Catalysis SL

Phase 2 Completed
40 enrolled
Gynecologic

Adnexal Diseases, Carcinoma, Endocrine System Diseases, Endocrine Gland Neoplasms, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Female, Genital Neoplasms, Female, Gonadal Disorders, Neoplasm Metastasis, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Urogenital Neoplasms, Female Urogenital Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡